No Data
Tibet Cheezheng Tibetan Medicine: 2024 Half-Year Performance Bulletin
Tibet Cheezheng Tibetan Medicine (002287.SZ) had a net income of 0.326 billion yuan in the first half of the year, a year-on-year increase of 4.42%.
Qizheng Tibetan Medicine (002287.SZ) released its 2024 half-yearly report. Within the reporting period, the company achieved a total operating revenue of 1.01 billion yuan, representing a 21.70% increase over the same period last year. The company achieved an operating profit of 0.367 billion yuan, which was a 7.85% increase over the same period last year; the net income attributable to shareholders of the listed company was 0.326 billion yuan, representing a 4.42% increase year-on-year; the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.228 billion yuan, representing a 4.30% increase over the same period last year; and the basic earnings per share was 0.6150 yuan.
As of June 28, 2024, the total number of shareholders of Tibet Cheezheng Tibetan Medicine (002287.SZ) is 20,044.
On July 2nd, Gelonhui reported that as of June 28th, 2024, the total number of shareholders in Tibet Cheezheng Tibetan Medicine (002287.SZ) was 20,044.
Tibet Cheezheng Tibetan Medicine (002287.SZ) annual equity distribution for 2023: 4.80 yuan per 10 shares, registration of shares on July 3.
Tibet Cheezheng Tibetan Medicine (002287.SZ) announced that the company's annual equity distribution plan for 2023 is: based on the company's existing total share capital excluding repurchased shares, RMB 4.80 per 10 shares will be distributed to all shareholders in cash (including tax). The equity distribution record date for this time is July 3, 2024, and the ex-dividend date is July 4, 2024.
Qizheng Tibetan Medicine (002287.SZ): Net profit of 97.468 million yuan in the first quarter increased 5.06% year-on-year
Gelonghui, April 26 | Qizheng Tibetan Pharmaceutical (002287.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 365 million yuan, up 23.37% year on year; net profit attributable to shareholders of listed companies was 97.468 million yuan, up 5.06% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 56.0285 million yuan, an increase of 77.42% year on year; basic earnings per share were 0.1,838 yuan.
Qizheng Tibetan Medicine (002287.SZ): 2023 net profit of 581 million yuan, plans to distribute 10 to 4.8 yuan
Gelonghui, April 18 | Qizheng Tibetan Medicine (002287.SZ) announced its 2023 annual report. In 2023, the company achieved operating income of 2,045 billion yuan, up 0.02% year on year; net profit attributable to shareholders of listed companies was 581 million yuan, up 22.99% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 370 million yuan, down 15.94% year on year; basic income per share was 1.0972 yuan; plans to distribute a cash dividend of 4.8 yuan (tax included) to all shareholders for every 10 shares.
No Data
